» Articles » PMID: 34768770

GnRH Antagonists with or Without Add-Back Therapy: A New Alternative in the Management of Endometriosis?

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Nov 13
PMID 34768770
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

To evaluate the effectiveness of a new class of medical drugs, namely oral gonadotropin-releasing hormone (GnRH) antagonists, in the management of premenopausal women with endometriosis-associated pelvic pain. We reviewed the most relevant papers ( = 27) on the efficacy of new medical alternatives (oral GnRH antagonists) as therapy for endometriosis. We first briefly summarized the concept of progesterone resistance and established that oral contraceptives and progestogens work well in two-thirds of women suffering from endometriosis. Since clinical evidence shows that estrogens play a critical role in the pathogenesis of the disease, lowering their levels with oral GnRH antagonists may well prove effective, especially in women who fail to respond to progestogens. There is a need for reliable long-term oral treatment capable of managing endometriosis symptoms, taking into consideration both the main symptoms and phenotype of the disease. Published studies reviewed and discussed here confirm the efficacy of GnRH antagonists. There is a place for GnRH antagonists in the management of symptomatic endometriosis. Novel algorithms that take into account the different phenotypes are proposed.

Citing Articles

Non-inferiority study to compare the efficacy of relugolix with dienogest for endometriosis-associated pain and usefulness of administering relugolix prior to dienogest (READY study): study protocol for a multicenter randomized controlled study.

Taniguchi F, Fukui M, Osuga Y, Harada T, Kitawaki J Trials. 2025; 26(1):41.

PMID: 39910584 PMC: 11800467. DOI: 10.1186/s13063-025-08750-9.


A preliminary study on the effects of Xiang Shao granules on reproductive endocrinology in drugged ovariectomised rats.

Jia Q, Tang H, Zhong X, Chen W, Wu Y, Wei W J Ovarian Res. 2024; 17(1):206.

PMID: 39425131 PMC: 11490142. DOI: 10.1186/s13048-024-01531-z.


Development and Application of a Physiologically Based Pharmacokinetic Model for Elagolix in the Adult and Adolescent Population.

Zhang X, Wang X, Li R, Zhang C, Du J, Zhao H Clin Pharmacokinet. 2024; 63(9):1357-1370.

PMID: 39060899 DOI: 10.1007/s40262-024-01402-2.


Advancements and Emerging Therapies in the Medical Management of Uterine Fibroids: A Comprehensive Scoping Review.

Krzyzanowski J, Paszkowski T, Szkodziak P, Wozniak S Med Sci Monit. 2024; 30:e943614.

PMID: 38837949 PMC: 11163935. DOI: 10.12659/MSM.943614.


Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).

Donnez J, Becker C, Taylor H, Carmona Herrera F, Donnez O, Horne A Hum Reprod. 2024; 39(6):1208-1221.

PMID: 38648863 PMC: 11144970. DOI: 10.1093/humrep/deae076.


References
1.
Bulun S, Cheng Y, Yin P, Imir G, Utsunomiya H, Attar E . Progesterone resistance in endometriosis: link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006; 248(1-2):94-103. DOI: 10.1016/j.mce.2005.11.041. View

2.
Wang S, Johnson S, Mitchell D, Soliman A, Vora J, Agarwal S . Cost-effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA. J Comp Eff Res. 2019; 8(5):337-355. DOI: 10.2217/cer-2018-0124. View

3.
Taylor H, Soliman A, Johns B, Pokrzywinski R, Snabes M, Coyne K . Health-Related Quality of Life Improvements in Patients With Endometriosis Treated With Elagolix. Obstet Gynecol. 2020; 136(3):501-509. PMC: 7431150. DOI: 10.1097/AOG.0000000000003917. View

4.
Anaf V, Simon P, El NAkadi I, Fayt I, Simonart T, Buxant F . Hyperalgesia, nerve infiltration and nerve growth factor expression in deep adenomyotic nodules, peritoneal and ovarian endometriosis. Hum Reprod. 2002; 17(7):1895-900. DOI: 10.1093/humrep/17.7.1895. View

5.
Ferrero S, Evangelisti G, Barra F . Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018; 19(10):1109-1125. DOI: 10.1080/14656566.2018.1494154. View